ストックスクリーナーアプリを入手
1.10
5.98%
-0.07
プレマーケット:
1.08
-0.02
-1.82%
前日終値:
$1.17
開ける：
$1.02
24時間の取引高:
573.61K
Relative Volume:
3.20
時価総額：
$51.58M
収益：
$8.98M
当期純損益:
$-48.79M
株価収益率:
-1.3802
EPS:
-0.797
ネットキャッシュフロー:
$-36.77M
1週間 パフォーマンス:
-3.51%
1か月 パフォーマンス:
-28.57%
6か月 パフォーマンス:
-47.87%
1年 パフォーマンス:
-57.69%
1日の値動き範囲:
$1.02
$1.1751
1週間の範囲:
$1.02
$1.2647
52週間の値動き範囲:
$1.02
$2.9319
InspireMD Inc. Stock (NSPR) Company Profile
Compare NSPR vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
1.10 | 51.58M | 8.98M | -48.79M | -36.77M | -0.797 |
ABT
Abbott Laboratories
|
87.17 | 151.83B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 113.08B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 99.87B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 83.21B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 47.80B | 6.30B | 1.07B | 1.34B | 1.8406 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-02 | 開始されました | Maxim Group | Buy |
| 2016-01-07 | 開始されました | Rodman & Renshaw | Buy |
| 2015-03-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2013-11-26 | 開始されました | Oppenheimer | Outperform |
InspireMD Inc. (NSPR) 最新ニュース
InspireMD, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
InspireMD anticipates FDA approval of original CGuard delivery system in Q3 2026 as it withdraws 2026 revenue guidance - MSN
InspireMD Q1 2026 earnings preview - MSN
NSPR: CGuard® Prime leverages clinical leadership and innovation to capture a growing carotid stenting market - TradingView
InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
NSPR: Q1 revenue up 122% year-over-year; U.S. relaunch expected after FDA approval in Q3 2026 - TradingView
InspireMD (NSPR) Q3 2025 Earnings Transcript - AOL.com
InspireMD (NSPR) Q4 2025 Earnings Transcript - AOL.com
Earnings call transcript: InspireMD beats Q1 2026 forecasts but faces operational pause - Investing.com
InspireMD Inc reports results for the quarter ended March 31Earnings Summary - TradingView
InspireMD (NASDAQ:NSPR) Q1 Beat Fails to Impress as Stock Slides - ChartMill
After a recall, InspireMD says another FDA decision is due in Q3 - Stock Titan
InspireMD (NSPR) doubles Q1 revenue, details recall costs and FDA milestones - Stock Titan
InspireMD Initiates Voluntary U.S. Recall of CGuard Prime 135 cm Carotid Stent Delivery System - marketscreener.com
InspireMD recalls CGuard Prime 135 cm carotid stent delivery system in US - Medical Buyer
InspireMD Says FDA Approved Application to Begin SwitchGuard Neuro Protection System CGUARDIANS III Study - Moomoo
FDA Approves InspireMD's Application to Initiate Study of Neuro Protection System -- Update - Moomoo
NSPR rallies after hours on FDA green light for key stroke-prevention trial despite withdrawn annual guidance - MSN
InspireMD Recalls CGuard Prime Delivery System, Pauses U.S. Launch - TipRanks
InspireMD IncRecall Follows Technical Perf - Moomoo
InspireMD Withdraws Guidance, Recalls CGuard Prime - marketscreener.com
InspireMD receives FDA approval for stroke device study By Investing.com - Investing.com Australia
FDA lets InspireMD start pivotal study of stroke-protection device - Stock Titan
InspireMD Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery System - The Manila Times
InspireMD receives FDA approval for stroke device study - Investing.com
InspireMD pauses U.S. launch of CGuard Prime 135 cm, withdraws 2026 revenue guidance; IDE approved for SwitchGuard TCAR study - TradingView
InspireMD Receives FDA Approval for CGUARDIANS III Pivotal Study of SwitchGuard Neuro Protection System - Quiver Quantitative
Stent launch stalls after U.S. recall; InspireMD eyes Q3 FDA nod - Stock Titan
Recall and FDA trial approval reshape InspireMD (NSPR) device outlook - Stock Titan
InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System - Weekly Voice
InspireMD (NYSE:NSPR) Stock Price Up 3.5%What's Next? - MarketBeat
InspireMD recently announced that the U.S. Food and Drug Administration (FDA) has officially approved its device exemption application for the pivotal Cguardians III study on the Switchguard neuroprotection system. - Bitget
NSPR Stock Price, Quote & Chart | INSPIREMD INC (NASDAQ:NSPR) - ChartMill
After plunging 15.2% in 4 weeks, here's why the trend might reverse for InspireMD (NSPR) - MSN
InspireMD to Announce First Quarter 2026 Financial Results - The Manila Times
InspireMD Stock Dips On Wider-Than-Expected Q1 Loss, But Retail Is Optimistic - MSN
InspireMD (NSPR) CEO Marvin Slosman reports 5.18% beneficial stake - Stock Titan
[ARS] InspireMD, Inc. SEC Filing - Stock Titan
InspireMD (NSPR) schedules 2026 shareholder meeting on director slate and share authorization - Stock Titan
InspireMD : April 2026 Investor Deck - marketscreener.com
Shareholder Lawsuit Launched Against InspireMD - National Today
Form 424B5Prospectus [Rule 424(b)(5)] - ADVFN
InspireMD (NSPR) asks shareholders to approve 150M→250M share increase - Stock Titan
After Dropping 15.2% Over the Past Four Weeks, This Is Why InspireMD (NSPR) Could See a Turnaround - Bitget
After Plunging 15.2% in 4 Weeks, Here's Why the Trend Might Reverse for InspireMD (NSPR) - Yahoo Finance
InspireMD (NYSE:NSPR) Trading Down 6.7%What's Next? - MarketBeat
Published on: 2026-04-06 18:18:37 - baoquankhu1.vn
Is InspireMD (NSPR) Stock Overpriced Now | Price at $1.49, Down 3.25%Popular Market Picks - UBND thành phố Hải Phòng
InspireMD, Inc. Enters Equity Distribution Agreement with BTIG, LLC – SEC 8-K Filing Details (April 2026) - Minichart
InspireMD Establishes New $75 Million ATM Program - TipRanks
According to the latest submitted documents, medical device company InspireMD Inc. has signed an equity distribution agreement with the sales agent. - Bitget
InspireMD Inc. (NSPR) 財務データ
収益
当期純利益
現金流量
EPS
0.41%
0.93%
大文字化:
|
ボリューム (24 時間):